Contact

Our portfolio

Amplio Pharma

Amplio Pharma’s proprietary NovoBio Med technology amplifies the efficacy of methotrexate (MTX), the first line, cornerstone drug used to treat a wide variety of autoimmune diseases. NovoBioMed is able to trap MTX at its target, resulting in a faster response and better efficacy at a lower dose.

  • Institute: Amsterdam UMC
Industry: Rheumatology, Therapeutics
  • Founding year: 2023
Visit website

Want to get in contact about Amplio Pharma?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Regenesance
Engineering antibodies to treat neurodegenerative and immune diseases.
InspectT
Enabling standard spectrometers to simultaneously measure both chemical composition and particle size by integrating patented, cost-effective Optical-DOSY flow cells.
ForceSense
Improving surgical skill development with the Lapron Boxtrainer, a laparoscopic training system.
Eddytec
Providing advanced defect detection for carbon composites in aerospace and wind energy.
Regenesance
Engineering antibodies to treat neurodegenerative and immune diseases.
InspectT
Enabling standard spectrometers to simultaneously measure both chemical composition and particle size by integrating patented, cost-effective Optical-DOSY flow cells.
ForceSense
Improving surgical skill development with the Lapron Boxtrainer, a laparoscopic training system.
Eddytec
Providing advanced defect detection for carbon composites in aerospace and wind energy.
Explore full AAV portfolio
Contact